Use of a highly-sensitive rapid diagnostic test to screen for malaria in pregnancy in Indonesia

Background: The sensitivity of rapid diagnostic tests (RDTs) for malaria is inadequate for detecting low-density, often
asymptomatic infections, such as those that can occur when screening pregnant women for malaria. The performance
of the Alere™ Ultra-sensitive Malaria Ag Plasmodium falciparum RDT (uRDT) was assessed retrospectively in
pregnant women in Indonesia.
Methods: The diagnostic performance of the uRDT and the CareStart™ Malaria HRP2/pLDH VOM (Plasmodium vivax,
Plasmodium ovale and Plasmodium malariae) Combo RDT (csRDT) were assessed using 270 stored red blood cell pellets
and plasma samples from asymptomatic pregnant women. These included 112 P. falciparum negative and 158
P. falciparum positive samples detected by a composite test (qPCR, LAMP, nPCR) as reference standard. Diagnostic
indicators: sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), diagnostic odds ratio
(DOR) and the level of agreement (kappa) were calculated for comparison.
Results: Compared with the reference test, the uRDT had a sensitivity of 19.6% (95% CI 13.9–26.8) and specificity of
98.2% (93.1–99.7%). The csRDT was 22.8% (16.7–30.3) sensitive and 95.5% (89.4–98.3) specific for P. falciparum infections.
Performance of the uRDT was non-significantly different to the csRDT (p = 0.169). RDT outcome was stratified by
qPCR cycling threshold (Ct), and performance of the RDTs was found to be comparable across parasite loads.
Conclusion: The uRDT performed similarly to the currently used csRDTs in detecting P. falciparum infections in
asymptomatic pregnant women. In these settings, molecular diagnostics are currently the most sensitive for malaria.